[1]
|
Freddie, B., Jacques, F., Isabelle, S., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Meyer, L.A., He, W.G., Sun, C.C., et al. (2018) Neoadjuvant Chemother-apy in Elderly Women with Ovarian Cancer: Rates of Use and Effectiveness. Gynecologic Oncology, 150, 451-459. https://doi.org/10.1016/j.ygyno.2018.06.020
|
[3]
|
万佳红, 唐晓旭. 血清及腹水肿瘤标志物诊断良恶性腹水的临床研究[J]. 国际检验医学杂志, 2017, 38(20): 2811-2812, 2815.
|
[4]
|
孙晨希, 刘贵生, 付佐君. CDX2/PAX8/CA125在不明来源癌性腹水诊断中的研究进展[J]. 中国临床研究, 2021, 34(4): 538-541.
|
[5]
|
Shender, V.O., Pavlyukov, M.S., Ziganshin, R.H., et al. (2014) Proteome-Metabolome Profiling of Ovarian Cancer Ascites Reveals Novel Components Involved in Intercellular Communication. Molecular & Cellular Proteomics: MCP, 13, 3558-3571. https://doi.org/10.1074/mcp.M114.041194
|
[6]
|
卢淮武, 吴斌, 许妙纯, 等. 《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2022, 38(3): 310-318.
|
[7]
|
宋玉霞, 赵涛, 王宏卫, 等. 卵巢癌腹水中不同肿瘤相关性巨噬细胞亚型IL-10、IL-12表达的差异[J]. 河北医科大学学报, 2017, 38(6): 676-679.
|
[8]
|
李晓峰, 张锐, 李金玲. 卵巢癌患者腹水和外周血中CA125和CD4~+CD25~+调节性T细胞含量监测的临床价值[J]. 中国妇幼保健, 2021, 36(14): 3199-3200.
|
[9]
|
Capellero, S., Erriquez, J., Battistini, C., et al. (2022) Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. International Journal of Molecular Sciences, 23, 833. https://doi.org/10.3390/ijms23020833
|
[10]
|
Bansal, A., Srinivasan, R., Rohilla, M., et al. (2020) Morphologic and Immunocytochemical Features of High-Grade Serous Carci-noma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology. American Journal of Clinical Pathology, 154, 103-114. https://doi.org/10.1093/ajcp/aqaa028
|
[11]
|
Mo, L.H., Bachelder, R.E., Kennedy, M., et al. (2015) Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78. Molecular Cancer Therapeutics, 14, 747- 756. https://doi.org/10.1158/1535-7163.MCT-14-0579
|
[12]
|
Huang, H., Li, Y.J., Lan, C.Y., et al. (2013) Clinical Sig-nificance of Ascites in Epithelial Ovarian Cancer. Neoplasma, 60, 546-552. https://doi.org/10.4149/neo_2013_071
|
[13]
|
Ford, C.E., Werner, B., Hacker, N.F., et al. (2020) The Untapped Po-tential of Ascites in Ovarian Cancer Research and Treatment. British Journal of Cancer, 123, 9-16. https://doi.org/10.1038/s41416-020-0875-x
|
[14]
|
Ahmed, N. and Stenvers, K.L. (2013) Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy- Based Translational Research. Frontiers in Oncology, 3, 256. https://doi.org/10.3389/fonc.2013.00256
|
[15]
|
Lane, D., Matte, I., Laplante, C., et al. (2016) CCL18 from Ascites Promotes Ovarian Cancer Cell Migration through Proline-Rich Tyrosine Kinase 2 Signaling. Molecular Cancer, 15, 58. https://doi.org/10.1186/s12943-016-0542-2
|
[16]
|
Siddiqui, I., Erreni, M., Kamal, M.A., et al. (2017) Differential Role of Interleukin-1 and Interleukin-6 in K-Ras-Driven Pancreatic Carcinoma Undergoing Mesenchymal Transition. Oncoimmunology, 17, e1388485.
https://doi.org/10.1080/2162402X.2017.1388485
|
[17]
|
Dalal, V., Kumar, R., Kumar, S., et al. (2018) Biomarker Potential of IL-6 and VEGF-A in Ascitic Fluid of Epithelial Ovarian Cancer Patients. Clinica Chimica Acta; International Journal of Clinical Chemistry, 482, 27-32.
https://doi.org/10.1016/j.cca.2018.03.019
|
[18]
|
Szender, J.B., Emmons, T., Belliotti, S., et al. (2017) Impact of As-cites Volume on Clinical Outcomes in Ovarian Cancer: A Cohort Study. Gynecologic Oncology, 146, 491-497. https://doi.org/10.1016/j.ygyno.2017.06.008
|
[19]
|
刘萍. 卵巢癌腹水与卵巢癌耐药的相关性研究[D]: [硕士学位论文]. 天津: 天津医科大学, 2016.
|
[20]
|
Szulc-Kielbik, I., Kielbik, M., Nowak, M., et al. (2021) The Implication of IL-6 in the Invasiveness and Chemoresistance of Ovarian Cancer Cells. Systematic Review of Its Potential Role as a Bi-omarker in Ovarian Cancer Patients. Biochimica et Biophysica Acta, 1876, Article ID: 188639. https://doi.org/10.1016/j.bbcan.2021.188639
|
[21]
|
李庆. 卵巢癌腹水形成的分子机制及治疗进展[J]. 系统医学, 2019, 4(22): 192-195.
|
[22]
|
Monavarian, M., Elhaw, A.T., Tang, P.W., et al. (2022) Emerging Perspectives on Growth Factor Metabolic Relationships in the Ovarian Cancer Ascites Environment. Seminars in Cancer Biology, 86, 709-719.
https://doi.org/10.1016/j.semcancer.2022.03.004
|
[23]
|
Zhang, S.B., Xie, B.F., Wang, L.J., et al. (2021) Macro-phage-Mediated Vascular Permeability via VLA4/VCAM1 Pathway Dictates Ascites Development in Ovarian Cancer. The Journal of Clinical Investigation, 131, e140315.
https://doi.org/10.1172/JCI140315
|
[24]
|
Lane, D., Matte, I., Garde-Granger, P., et al. (2015) Inflamma-tion-Regulating Factors in Ascites as Predictive Biomarkers of Drug Resistance and Progression-Free Survival in Serous Epithelial Ovarian Cancers. BMC Cancer, 15, Article No. 492. https://doi.org/10.1186/s12885-015-1511-7
|
[25]
|
Jie, X.X., Du, M., Zhang, M., et al. (2022) Mutation Analysis of Circulating Tumor DNA and Paired Ascites and Tumor Tissues in Ovarian Cancer. Experimental and Therapeutic Medicine, 24, 542.
https://doi.org/10.3892/etm.2022.11479
|
[26]
|
Trachana, S.P., Pilalis, E., Gavalas, N.G., et al. (2016) The Develop-ment of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. PLOS ONE, 11, e0156403.
https://doi.org/10.1371/journal.pone.0156403
|
[27]
|
Fumagalli, C., Rappa, A., Casadio, C., et al. (2019) Next-Generation Sequencing-Based BRCA Testing on Cytological Specimens from Ovarian Cancer Ascites Reveals high Concordance with Tumour Tissue Analysis. Journal of Clinical Pathology, 73, 168-171. https://doi.org/10.1136/jclinpath-2019-206127
|
[28]
|
Kolomeyevskaya, N., Eng, K.H., Khan, A.N.H., et al. (2015) Cytokine Profiling of Ascites at Primary Surgery Identifies an Interaction of Tumor Necrosis Factor-α and Interleukin-6 in Predicting Reduced Progression-Free Survival in Epithelial Ovarian Cancer. Gynecologic Oncology, 138, 352-357. https://doi.org/10.1016/j.ygyno.2015.05.009
|
[29]
|
Carroll, M.J., Kaipio, K., Hynninen, J., et al. (2022) A Subset of Secreted Proteins in Ascites Can Predict Platinum- Free Interval in Ovarian Cancer. Cancers, 14, 4291. https://doi.org/10.3390/cancers14174291
|
[30]
|
Coosemans, A.N., Baert, T., D’heygere, V., et al. (2019) Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. Anticancer Research, 39, 5953-5962.
https://doi.org/10.21873/anticanres.13800
|
[31]
|
Kipps, E., Tan, D.S.P. and Kaye, S.B. (2013) Meeting the Challenge of Ascites in Ovarian Cancer: New Avenues for Therapy and Research. Nature Reviews. Cancer, 13, 273-282. https://doi.org/10.1038/nrc3432
|
[32]
|
黄于峰. 腹水及血清CA125动力学对高级别浆液性卵巢癌化疗敏感性及预后的相关性分析[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2021.
|
[33]
|
Almeida-Nunes, D.L., Mendes-Frias, A., Silvestre, R., et al. (2022) Immune Tumor Microenvironment in Ovarian Cancer Ascites. International Journal of Molecular Sciences, 23, Article 10692.
https://doi.org/10.3390/ijms231810692
|